Europe

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study
Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe
Cancer cure for 32 cancer types: results from the EUROCARE-5 study
Cancer data quality and harmonization in Europe: the experience of the BENCHISTA Project - international benchmarking of childhood cancer survival by stage
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study
Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study
Economic evaluation of cancer registration in Europe
Embryonal cancers in Europe
Epidemiology of glial and non-glial brain tumours in Europe
Epidemiology of rare cancers and inequalities in oncologic outcomes
Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes
Geographical and temporal differences in gastric and oesophageal cancer registration by subsite and morphology in Europe
Geographical variability in survival of European children with central nervous system tumours
Incidence and survival of rare urogenital cancers in Europe
Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002
Incidence, survival and prevalence of myeloid malignancies in Europe
Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study
Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting
Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project
Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study

Pagina 1 di 2

Inizio
Indietro
1
2
Avanti
Fine

Questo sito web utilizza cookies per fornirti una migliore esperienza di navigazione. Scopri di più.